4th Quarter - Report

PODESTA GROUP, INC. for AMGEN

Firm
Client
Income
$90,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part B reimbursement and coverage of dialysis products.

LobbyistCovered position, as disclosed
SHARON COHEN —
ANTHONY PODESTA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.J.Res. 117 (112th), H.R. 5973 (112th), H.R. 5651 (112th), H.R. 6433 (112th), S. 2375 (112th), S. 3187 (112th)

Health Issues HCR

Prescription Drug User Fee Act reauthorization. Biosimilar products. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012.

LobbyistCovered position, as disclosed
SHARON COHEN —
OSCAR RAMIREZ —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3187 (112th), H.R. 6433 (112th), H.R. 5651 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.